Overview

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Status:
Recruiting

Trial end date:
2028-12-27

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.

Phase:

Phase 3

Details

Lead Sponsor:

Ferring Pharmaceuticals